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Abstract: P-type ATPases form a large and ubiquitous superfamily of ion and lipid transporters that
use ATP (adenosine triphosphate) to carry out their function. The IB subclass (PIB-ATPases) allows
flux of heavy metals and are key players in metal detoxification, critical for human health, crops,
and survival of pathogens. Nevertheless, PIB-ATPases remain poorly understood at a molecular level.
In this study, nanobodies (Nbs) are selected against the zinc-transporting PIB-ATPase ZntA from
Shigella sonnei (SsZntA), aiming at developing tools to assist the characterization of the structure and
function of this class of transporters. We identify six different Nbs that bind detergent stabilized
SsZntA. We further assess the effect of the Nbs on the catalytic function of SsZntA, and find that five
nanobodies associate without affecting the function, while one nanobody significantly reduces the
ATPase activity. This study paves the way for more refined mechanistical and structural studies of
zinc-transporting PIB-ATPases.
Keywords: P-type ATPase; nanobody; llama; Zinc-transport; Zinc-transporting P-ATPase; ZntA
1. Introduction
The protein superfamily of P-type ATPases is formed by phylogenetically related pumps that
actively transport ions and lipids across biological membranes of prokaryotes and eukaryotes [1] at
the expense of adenosine triphosphate (ATP). They are divided in five subfamilies (PI-PV) based on
sequence similarity and transport specificity [2]. PI-ATPases transport cations, with the PIB-subclass
being specific for heavy metals such copper and zinc. Noteworthy members of the other subfamilies
include the calcium and sodium-potassium ATPases of PII and the proton ATPase of PIII. The focus
here is on class 2 PIB-ATPases, PIB-2-ATPases, which comprises zinc-transporting P-type ATPases.
These ATPases are relatively poorly characterized from a mechanistic and functional point of view,
and only E2 states (metal-free) have been resolved structurally [3]. One reason is that metals such
as zinc render these targets unstable, and another that there are no identified compounds that can
bind specifically and exclusively to several specific states (including metal bound E1 conformations)
of PIB-ATPases. The overall structural architecture is conserved in all P-type ATPases, with four
domains [4]: The soluble domains, P (phosphorylation), N (nucleotide binding), and A (actuator),
and the M domain in the transmembrane region. The P domain contains the highly conserved
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aspartic acid—lysine—threonine—glycine—threonine (DKTGT) motif with the catalytic aspartate that
is targeted by ATP stimulated autophosphorylation. The N domain is responsible for orienting the
ATP towards the P domain. The A domain comprises the conserved threonine—glycine—glutamic
acid (TGE) loop, which allows for dephosphorylation of the catalytic aspartate in the P-domain and
the M-domain is composed by a variable number of helices that enclose membranous ion-binding
site(s) that are critical for transport. In addition, zinc transporting PIB-2-ATPases possess one or more
soluble subfamily-specific domains known as heavy metal-binding domains (HMBDs), whose function
remains unclear [5]. These domains work in a tightly coupled manner in order to achieve transport,
and the reaction cycle is summarized in the so called Post-Albers scheme [6–8] (Figure 1).
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Figure 1. Post-Albers scheme of PIB-2-ATPases. The E1 (high zinc affinity) and E2 (low zinc
affinity) state of the enzy e alternate, and couple ATP (adenosine triphosphate) hydroly is to
the export of zinc. The E1 state accepts on zinc (Zn2+) ion and ATP from intracellular sid ,
which promotes autophosphorylation, reaching the zinc occluded Zn·E1-P state and releasing ADP
(adenosine diphosphate). Completion of phosphorylation triggers considerable conformational changes
that opens the pump towards the outside, allowing release of zinc in the E2-P state. Metal discharge is
associated with auto dephosphorylation, liberation of inorganic phosphate (Pi), and allows the enzyme
to reach the E2 conformation. The domains are represented as follows: The actuator (A) domain
in yellow, the phosphorylation (P) domain in blue, the nucleotide-binding (N) domain in red, the
transmembrane domain in light orange. Features specific for PIB-ATPases are shown in light blue, and
includes two transmembrane helices and heavy-metal binding domain(s) (HMBD).
Antibodies, or immunoglobulins, are large plasma proteins that play a fundamental role in
protection against pathogens, such as microorganisms, and are used for numerous basic and applied
science applications. Immunoglobulin gamma 1 (IgG1), which is the most abundant immunoglobulin,
comprises four polypeptide chains: Two heavy chains, each formed by a variable domain (VH)
and three constant domains (CH1, CH2, and CH3), and two light chains, composed by a variable
(VL) and a constant (CL) domain. The paratope (antigen binding-site) is formed by the VL and VH
domains and mediates the interaction with the antigen [9]. However, heavy-chain only antibodies
are present in certain species [10]: They are smaller (about 75 kDa) than other antibody isotypes and
are formed by two heavy chains, each containing a VHH, CH2, and CH3 domain. Their paratope
permits antigen-recognition despite being formed by a single VHH domain only, paving the way for
the developme t of single-domain antibodies also called nanobodies. These engineered antibodies are
derived from such heavy-chain only antibodies and consist of a single polypepti e chain (about 13 kDa)
folding into a var able domain (VHH). They can be obtained by immunization o camelids (e.g., ll mas)
with t e target antigen, followed by generation of phage display libraries and screening for antigen
binding [11].
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The aim of this work is to isolate nanobodies (Nbs) that selectively associate with the
zinc-transporter, ZntA, from Shigella sonnei (SsZntA), the target employed previously for structural
characterization of PIB-2-ATPases [3], to develop inhibitors for further structural and functional studies.
We successfully raise and purify Nbs against SsZntA and perform experiments to assess binding and
inhibition capacities. Notably, we identify six Nbs, which bind specifically to SsZntA, including one
that exhibits an inhibitory effect on the ATPase activity.
2. Materials and Methods
2.1. SsZntA Production
In the following text we refer to the manufacturers Sigma-Aldrich with location in Schnelldorf,
Germany; and to VWR with location in Søborg, Denmark, unless other is stated. The gene for ZntA
from the bacterium Shigella sonnei (UniProtID Q3YW59) was cloned in the vector, pET22 (Merck,
Novagen®, Darmstadt, Germany), containing an amino-terminus tag of eight histidine residues (HisTag)
for downstream affinity chromatography purification and a cleavage site for TEV protease (TEVp) to
allow removal of the HisTag. The construct, pET22-HisTag-SsZntA, was transformed into the E. coli
C43(DE3) expression strain and cells were grown in Terrific-Broth medium (12 % peptone (Sigma-Aldrich),
24% yeast extract (Sigma-Aldrich), 4% glycerol (VWR), 50 mM Phosphate buffer pH 7 (VWR)) at 37 ◦C
until OD600 reached 1. Then, protein production was induced with 1 mM isopropyl-β-D-thiogalactoside
(IPTG) (Biosynth AG, Staad, Switzerland) at 18 ◦C for 24 h. Cells were harvested at 8000× g for 15 min,
and resuspended at a concentration of 5 mL/g wet cells in buffer containing 50 mM Tris-HCl pH
8 (Sigma-Aldrich), 200 mM KCl (VWR), 20% v/v glycerol (VWR), 5 mM β-mercaptoethanol (BME)
(VWR), 1 SIGMAFASTTM protease inhibitor tablet (Sigma-Aldrich) per 6 L culture, and then stored
at −20 ◦C. To the thawed cells, a final concentration of 1 mM MgCl2 (VWR), 2 µg/mL DNase I
(Sigma-Aldrich) and 1 mM phenylmethanesulphonyl fluoride (PMSF) (Sigma-Aldrich) were added
before lysis. The solution was passed through a Constant Systems cell disruptor (Constant Systems
Limited, Daventry, UK) twice at 25 kpsi, large cell debris were spun down at 20,000× g for 40 min,
and membranes were isolated by ultracentrifugation at 190,000× g for 3 h. The membrane pellet was
resuspended in 20 mM Tris-HCl pH 7.5, 200 mM KCl, 20% v/v glycerol, 1 mM MgCl2, 5 mM BME,
1 mM PMSF at 3 mg (total protein) per mL (buffer), and solubilized in 1% w/v n-Dodecyl-β-D-maltoside
(DDM) (Anatrace, Maumee, OH, USA) for 1.5 h, followed by ultracentrifugation at 190,000× g for
45 min to remove insolubilized material. The supernatant from 6 L culture was adjusted to 50 mM
imidazole (Sigma-Aldrich) and 500 mM KCl prior to loading on a 5 mL HisTrap HP (GE Healthcare,
Life Sciences, Uppsala, Sweden) equilibrated in buffer containing 20 mM Tris-HCl pH 7.5, 200 mM KCl,
20% v/v glycerol, 1 mM MgCl2, 0.015% w/v octaethylene glycol monododecyl ether (C12E8) (Nikko
Chemicals Co., Ltd., Tokyo, Japan), 5 mM BME, using an Äkta pure chromatographic system (GE
Healthcare, Life Sciences, Uppsala, Sweden), and was eluted with the same buffer with 500 mM imidazole
added. Protein containing fractions were pooled and treated with TEVp to remove the HisTag while
dialyzing to diminish the excess of imidazole. The cleaved sample was loaded on the HisTrap again
(Reverse-affinity chromatography or R-IMAC) to separate uncleaved (HisTagged) protein and the TEVp;
the flow through was collected and tested by Western-blot using a conjugated antibody against 6×
HisTag (6×His mAb-HRP conjugated by Takara® Bio Europe AB, Göteborg, Sweden) to assess cleavage.
The cleaved sample was concentrated to 12 mg/mL and run on a 24 mL size-exclusion chromatography
(SEC) column with Superose6 beads (GE Healthcare, Life Sciences, Uppsala, Sweden) equilibrated in
SEC buffer (20 mM MOPS (3-(N-morpholino)propanesulfonic acid) (VWR) pH 6.8, 80 mM KCl, 20% v/v
glycerol, 3 mM MgCl2, 0.03% w/v DDM or 0.015% w/v C12E8, 5 mM BME). The fractions corresponding to
the main peak were collected, assessed for purity by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide
gel electrophoresis) (Thermo Fisher Scientific, Roskilde, Denmark), concentrated to 10 mg/mL, and stored
at −80 ◦C.
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2.2. LpCopA and MmCadA Production
CopA from Legionella pneumophila (LpCopA, UniProtID Q5ZWR1) and CadA from Mesorhizobium
metallidurans (MmCadA, UniProtID I4IY19) were produced with the same buffers as SsZntA, but with
somewhat different approaches. LpCopA was cloned in the pET22 vector, without any affinity
chromatography tag nor cleavage site, and was purified by Ni2+-affinity chromatography exploiting
the endogenous histidine rich amino-terminus (no engineered HisTag). MmCadA was cloned in
the pET52 vector (Merck, Novagen®, Darmstadt, Germany) that includes an N-terminal Strep-tag II
with a HRV 3C cleavage site and was purified by StrepTactin® Superflow® (IBA GmbH, Göttingen,
Germany) [12] affinity chromatography at pH 7.8, followed by SEC at pH 7.4; this tag does not bind
metal ions and therefore does not need to be removed.
2.3. Llama Immunization and Nanobodies Identification
Llama immunization and library generation was performed as previously described, now using
a mixture of proteins including purified SsZntA for immunization [13]. Briefly, SsZntA solubilized
in 0.03% w/v DDM were injected four times (100 µg/injection) during a period of 12 weeks.
The immunization was performed under the permit of Capralogics Inc., which provides a healthy
housing environment for all animals and adheres strictly to the United States Department of Agriculture
Animal Welfare Act regulations for Animal Care and Use. Peripheral blood mononuclear cells
(PMBCs) were isolated with Ficoll paque plus (GE healthcare, Life Sciences, Uppsala, Sweden),
and total RNA were extracted using a RNeasy plus kit (Qiagen, Hilden, Germany). cDNA was
generated with Superscript III first strand (Invitrogen) and amplified using primers specific for the
VHH genes. PCR products were cloned into a phagemid vector designed to express Nbs as pIII
fusions and with a C-terminal E-detection tag. VCSM13 helper phages were used for generation of
a M13 phage-display library. For selection, 20 µg biotinylated SsZntA (solubilized in 0.015% w/v
C12E8) bound to streptavidin beads were blocked in SEC buffer (containing 0.015% w/v C12E8 and
supplemented with 2% w/v bovine serum albumin (BSA) (Sigma-Aldrich) for 30 min. 5 × 1013 M13
phage particles were incubated with the protein for 1 h before the beads were washed 15 times with
SEC buffer (with 0.015% w/v C12E8). Elution of the bound phage particles were achieved by addition
of 500 µL of 0.2 M glycine (Sigma-Aldrich) pH 2.2 for 10 min, which were added to 75 µL of 1 M
Tris pH 9.1 for neutralization before being added to E. coli ER2738 cells. Cells were incubated for 1 h
at 37 ◦C and plated on agar plates with 2% w/v glucose (Sigma-Aldrich). The enriched library was
amplified and used in a second round of phage display performed as the first round, but with 1 µg
SsZntA and 2 × 1012 M13 phage particles. For ELISA, single colonies were transferred to a 96-well
plate format and grown for 4 h in LB medium, before Nb production was induced by addition of IPTG
to 0.8 mM. The plate was incubated by shaking overnight at 30 ◦C. Next, the plate was centrifuged
and 50 µL of the supernatant was transferred to an ELISA plate coated with a total of 50 µg SsZntA in
SEC buffer (with 0.015% w/v C12E8) blocked with 2% w/v BSA. After incubation for 1 h, the plate was
washed four times with SEC buffer (with 0.015% w/v C12E8, without BME), and the anti-E-tag-HPR
antibody (Bethyl Laboratories Inc., Montgomery, TX, USA) was added. The plate was then washed
four times in SEC buffer (with 0.015% w/v C12E8, without BME) followed by the addition of 50 µL
3,3′,5,5′-tetramethyl-benzidine (Sigma-Aldrich). The reaction was quenched by addition of 50 µL of
1 M HCl and absorbance was measured at 450 nm. Positive phagemids were sequenced and subcloned
in pET22, containing a PelB signal at the amino-terminus for periplasmic secretion and a 6xHisTag at
the carboxyl-terminus.
2.4. Nanobodies Sequence Analysis
ELISA-identified Nb hits were sequenced and the obtained sequences were aligned using the
SeaView software (version 4.7, PRABI-Doua, Lyon, France) [14], and a phylogenetic tree was built
using the BLOSUM62 matrix. The aligned sequences were visualized using the Sequence Manipulation
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Suite© (Multiple Align Show) (version 2, Paul Stothard, University of Alberta, Edmonton, NA,
Canada) [15] to highlight the level of identity with a threshold of 90%, which allowed selection
of non-redundant Nbs for downstream efforts. The predicted secondary structure was obtained
combining the predictions from ABody Builder Antibody Modelling software (Oxford Protein
Informatics Group, Oxford, UK) [16] and iCAN analysis platform for nanobodies (Southeast University,
Nanjing, Jiangsu Province, China) [17].
2.5. Nanobodies Production
The vectors containing 11 selected Nbs (Nb1 to Nb11) were transformed in E. coli BL21 strain and
grown in 2 L Terrific Broth medium each, at 37 ◦C until OD600 of 0.6. The expression was induced with
1 mM IPTG at 18 ◦C over-night. Cells were harvested at 8000× g for 15 min and solubilized in 30 mL Nb
buffer (20 mM Tris-HCl pH 7.5, 400 mM KCl, 20 mM imidazole) prior to sonication and centrifugation at
25,000× g for 20min. Nb proteins were purified from the clarified supernatant by incubation with 1 mL
Ni2+ beads (Ni SepharoseTM 6 Fast Flow) (GE Healthcare, Life Sciences, Uppsala, Sweden) for 1 h at 4 ◦C,
followed by 3 washes in Nb buffer and elution in 15 mL Nb buffer with 400 mM imidazole added. Next,
the eluted Nbs were concentrated to 10–15 mg/mL and run on a SEC column with SEC buffer (20 mM
MOPS pH 6.8, 80 mM KCl, 20% v/v glycerol, 3 mM MgCl2, 0.015% w/v C12E8) without reducing agent.
The main peak was collected, concentrated to 5 mg/mL (370 µM), and stored at −80 ◦C.
2.6. Functional Assay
2.6.1. SEC Co-Elution
Samples of SsZntA (40 µM) were incubated with Nb from 1 to 11 (40 µM) in 40 mM MOPS
pH 6.8, 80 mM KCl, 20% v/v glycerol, 1 mM MgCl2, 1 mM TCEP (tris(2-carboxyethyl) phosphine)
(Sigma-Aldrich), 0.15 mg/mL C12E8 for 30 min at room temperature in a final volume of 50 µL and run
on analytic-scale SEC (column volume of 2.4 mL, flow 0.04 mL/min) equilibrated with the same buffer,
to separate SsZntA-Nb complex from unbound proteins. Then, fractions were run on a denaturing
SDS-PAGE to visualize the presence of SsZntA and Nb. For the Nbs that showed complex formation,
the assay was scaled-up to obtain more reproducible and stable signals: 40 µM SsZntA was incubated
with 100 µM Nb in 50 µL and then diluted to 500 µL prior to running in a medium-scale SEC (column
volume of 24 mL, flow 0.05 mL/min).
2.6.2. Ni-NTA Co-Elution
In this assay, 13 nmol of SsZntA were incubated with 44 nmol of one of Nb1-2-4-5-8-9 in 20
mM MOPS pH 7.5, 200 mM KCl, 20% v/v glycerol, 1 mM MgCl2, 0.015% w/v C12E8, 5 mM BME,
for 1 h on ice in a final volume of 500 µL. The samples were then adjusted to 400 mM KCl and 50
mM imidazole, and run on a 1 mL HisTrap HP (GE Healthcare, Life Sciences, Uppsala, Sweden)
equilibrated with the same buffer at 0.3 mL/min. Fractions were collected and run on a SDS-PAGE
gel, then stained with InVision™ HisTag In-gel Stain (Thermo Fisher Scientific, Roskilde, Denmark),
according to the manual, to assess the presence of HisTagged proteins followed by Coomassie-staining
for total protein detection.
2.6.3. ATPase Activity Assay
The Baginski assay was used to measure ATPases activity and was conducted as previously
described [3]. Briefly, 0.8 µM SsZntA was incubated with no Nb, 1.6 µM Nb 1 to 9, 1.6 µM AlF3, 2 mM
AlF3, and 0.2, 0.4, 0.8, 1.2, 1.6, 2, 2.4, 2.8, 3.2, 6.4 µM Nb9 in 40 mM MOPS pH 6.8, 150 mM NaCl,
5 mM MgCl2, 20 mM (NH4)2SO4 (VWR), 20 mM L-cysteine (VWR), 5 mM NaN3 (Sigma-Aldrich),
0.25 mM Na2MoO4 (Sigma-Aldrich), 1.2 mg/mL soybean lipids (Sigma-Aldrich), 0.3% w/v C12E8,
0.5 mM ZnSO4 (Alfa Aesar by Thermo Fisher Scientific, Karlsruhe, Germany), in a total volume of
50 µL for 1 h at room temperature and the assay was started by addition of 5 mM ATP. The reaction
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was stopped after 15 min and after 30 min by adding 50 µL Stop solution (2.5% w/v ascorbic acid
(Sigma-Aldrich), 0.4 M HCl, 0.48% w/v (NH4)6Mo7O24 (Fluka Analytical, Bucharest, Romania),
0.8% w/v SDS (Sigma-Aldrich)) and then 75 µL of arsenic solution (2% w/v arsenite (Sigma-Aldrich,
2% v/v acetic acid (VWR), 3.5% w/v sodium citrate (VWR)), respectively. The absorbance was
measured in a microplate reader at 860 nm and the signal normalized with a sample without protein
as phosphate background. When testing Nb9 with LpCopA and MmCadA, the same conditions were
applied, except the use of CuSO4 as a metal ion with LpCopA.
3. Results
3.1. Isolation of Native SsZntA
SsZntA was produced in E. coli C43 cells and initially purified by immobilized metal affinity
chromatography (IMAC). The 8× histidine tag (HisTag) was removed using the TEVp cleavage site,
which is important since the HisTag can bind zinc and other metals, potentially interfering with activity
and binding assays. Detergent solubilized SsZntA was purified by HisTag-based affinity chromatography
and treated with TEVp to remove the HisTag and subjected to affinity purification again, achieving
complete separation of cleaved SsZntA, uncleaved (HisTagged) SsZntA, and HisTagged TEVp (Figure 2).
The flow-through of the second affinity chromatography (R-IMAC) contained completely cleaved and
pure SsZntA, while uncleaved SsZntA and TEVp were present in fractions containing 250 mM and
500 mM imidazole, respectively. SsZntA was further purified using size-exclusion chromatography (SEC),
achieving a high degree of purity, as assessed by SDS-PAGE, and homogeneity, as assessed by SEC
(Figure 3). The final yield of SsZntA is 5 to 10 mg per liter of culture.
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Clarified solubilized membranes, lane 3: Affinity-chromatography purified SsZntA (with HisTag), lanes 
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Figure 2. Purificaiton of the zinc-transporter SsZntA from Shigella sonnei: (Reverse-affinity
chromatography) R-IMAC. (a) Reverse (second) affinity chromatography profile: The first 60 mL
represent the flow-through containing cleaved SsZntA (without HisTag); at 80 mL, corresponding to
250 mM imidazole, uncleaved SsZntA is eluted; while at 90 mL, at 500 mM imidazole, HisTagged TEVp
is eluted. (b) On top, Coomassie stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and on the bottom, Western blot anti-HisTag; lane 1: Solubilized membranes, lane 2:
Clarified solubilized membranes, lane 3: Affinity-chromatography purified SsZntA (with HisTag),
lanes 4 to 6: Flow through of reverse affinity chromatography (SsZntA without HisTag) corresponding
to retention volume from 0 mL to 60 mL, lanes 7 to 9: Eluted fractions corresponding to retention
volume of 80, 85, and 90 mL, respectively.
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Figure 3. SsZntA purification: SEC. (a) Elution profile from a Superose6 size-exclusion column with
a column volume (CV) = 24 mL: The main peak elutes at 0.6 CV, followed by minor contaminants.
(b) Coomassie-stained SDS-PAGE containing the SEC fractions collected at 0.4, 0.5, 0.6, 0.7 CV; upper
band at 150 kDa is possibly SsZntA dimers (due to SDS artifacts).
3.2. Isolation of Nanobodies
The purified SsZntA sample (in 0.03% w/v DDM) was used for llama immunization with multiple
injections during a period of 12 weeks. We generated an Nb-library and, following two rounds of
phage-display followed by enzyme-linked immunosorbent assay ELISA analysis, we found about 100
positive clones. These were reduced for highly redundant ones, resulting in 45 different Nb sequences
that were grouped in three main families (Figure 4a). We decided to investigate 11 Nbs covering most
of the overall sequence variability: Nb1, Nb2, and Nb3 belong to the first family; Nb4 and Nb5 to
the second family; Nb6 and Nb7 to the third family; Nb8, Nb9, Nb10, and Nb11 did not fit in the
previous families and are therefore considered outliers. Figure 4b displays the primary structures of the
selected 11 Nbs, where the portions corresponding to the three complementarity-determining regions
(CDRs), as well as the predicted conserved secondary structure, are indicated. We then expressed
and purified the selected 11 Nbs (with HisTag) and tested them for SsZntA binding and inhibition.
Expression in E. coli BL21 yielded 4–5 g wet cell weight, which resulted in 9–13 mg affinity-purified
Nb, per liter of culture. Nb3 precipitated following affinity-chromatography and further work with it
was, therefore, discontinued. The purified Nbs were subjected to SEC, achieving relatively pure Nb
samples as analyzed using SDS-PAGE (Figure 5c). Purified SsZntA was tested with three different
assays to assess binding (size-exclusion and nickel-affinity chromatography) and inhibitory (ATPase
activity) properties of the purified Nbs.
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Figure 5. Nanobody purification. Samples from purification of Nb1 are representative of all the assessed 
Nbs. (a) Samples from insoluble fraction (pellet, P), flow-through of the IMAC (FT), first and third wash 
of Ni2+-beads (W1 and W3, respectively), and eluted fraction containing Nb1 loaded on Coomassie-
stained SDS-PAGE. (b) SEC (24mL, Superose75) elution profile: The main peak elutes at 0.6 CV with 
only minor contaminants. (c) Coomassie-stained SDS-PAGE of SEC-purified Nbs: Nbs have a molecular 
weight of approximately 13.5 kDa. 
Figure 4. Sequence analysis of the identified Nbs. (a) Phylogenetic tree of 45 Nb sequences: The three
main families of Nbs are highlighted by colored boxes: The first family (blue box) includes Nb1-2-3,
the second family (green) includes Nb4-5, the third family (ochre) is composed of two subfamilies,
which include Nb6 and Nb7, while Nb8-9-10-11 were sampled as outliers. (b) Sequence alignment of
the 11 selected Nbs containing the predicted secondary structure (β-sheets are shown as green arrows),
the complementarity-determining regions (CDR1 to 3), and the conserved disulphide bond (orange
line). Identical (90% threshold) residues are in dark yellow while similar amino acids in light yellow.
Nbs that bind to SsZntA, but do not inhibit activity, are represented with a green name (Nb1-2-4-5-8),
while in red, the Nb that significantly inhibits ATPase activity (Nb9). The Nbs that precipitated during
purification (Nb3) or that caused precipitation of SsZntA (Nb6-7-10-11) are represented in black.
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Figure 5. Nanobody purification. Samples from purification of Nb1 are representative of all the
assessed bs. (a) Samples from insoluble action (pellet, P), flow-th ough of the IMAC (FT), fir t and
third wash of Ni2+-beads (W1 and W3, resp ctively), and eluted raction containing Nb1 loaded on
Coomassie- tained SDS-PAGE. (b) SEC (24mL, Superose75) elution profile: The main peak elutes at 0.6
CV with only minor contaminants. (c) Coomassie-stained SDS-PAGE of SEC-purified Nbs: Nbs have a
molecula weight of approximately 13.5 kDa.
Antibodies 2018, 7, 39 9 of 15
3.3. Size-Exclusion Chromatography (SEC) Co-Elution
Nbs were incubated with SsZntA and subjected to SEC to assess complex formation. We tested
the binding in a small-scale size-exclusion column (2.4 mL) and in a medium-scale column (24 mL).
The latter was used only on Nbs, which proved to bind to SsZntA in order to obtain a more stable
signal and improve the signal-to-noise ratio. The chromatogram reported in Figure 6a is acquired from
the medium scale column obtained from Nb1 and is representative of those obtained from Nb2-4-5-8-9
(results not shown), and shows the first peak at 0.6 CV (14.5 mL) containing the SsZntA-Nb complex
and the second peak at 0.85 CV (20.5 mL) containing unbound Nb. The overlaying dashed and
dotted lines represent the chromatograms obtained from Nb1 and SsZntA, respectively, under the
same conditions. As summarized in Table 1, six Nbs (Nb1-2-4-5-8-9) displayed co-elution, suggesting
SsZntA-Nb interaction. Nb6-7-10-11 caused precipitation of SsZntA and hence these Nbs were not
tested in subsequent assays.
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Table 1. Size-exclusion chromatography co-elution results. 
Tested Nb Binding Precipitation 
Nb1 + - 
Nb2 + - 
Nb4 + - 
Nb5 + - 
Nb6 N.D. + 
Nb7 N.D. + 
Nb8 + - 
Nb9 + - 
Nb10 N.D. + 
Nb11 N.D. + 
Not determined (N.D.): Due to sample precipitation, binding could not be assessed. 
3.4. Affinity Purification Co-Elution 
The engineered HisTag of the Nbs was used to assess binding, as illustrated in Figure 7. Nb1-2-4-
5-8-9 were incubated with HisTag-free SsZntA and subjected to HisTag-based affinity chromatography. 
Figure 6. Ss t - complex analysis using size- xclusion chromatography. (a) Black line:
Chro atogra (40 µM) incubated with Nb1 (100 µM) in a final volume of 50 µL (then
diluted to 500 µM) and un t rough a size-exclusion column (Superose6, 1 CV = 24 mL) showing a pe k
at 0.6 CV, which contains the SsZntA-Nb complex, and a pe k at 0.85 CV, w ich contains unbound Nb.
The dashed line presents the chromatogram of Nb1 alone, while the dotted line the one from SsZntA
alo e (under th same c dition). (b) Coomassie-stained SDS-PAGE gel of the fractions collected at
0.35, 0.5, 0.55, 0.6, 0.65, 0.8, 0.85, 0.9, 1 CV.
Table 1. Size-exclusion chromatography co-elution results.
Tested Nb Binding Precipitation
Nb1 + -
Nb2 + -
Nb4 + -
Nb5 + -
Nb6 N.D. +
Nb7 N.D. +
Nb8 + -
Nb9 + -
Nb10 N.D. +
Nb11 N.D. +
Not determined (N.D.): Due to sample precipitation, binding could not be assessed.
3.4. Affinity Purification Co-Elution
The engineered HisTag of the Nbs was used to assess binding, as illustrated in Figure 7.
Nb1-2-4-5-8-9 were incubated with HisTag-free SsZntA and subjected to HisTag-based affinity
chromatography. The samples were then subjected to SDS-PAGE and tained with InVision® HisTag
Antibodies 2018, 7, 39 10 of 15
In-gel staining to evaluate the presence of the HisTag in the protein bands. The results in Figure 8
represent control experiments. Panel (a) confirms that the HisTag-free SsZntA appears in the
flow-through and is therefore lacking Ni2+-binding capacity; panel (b) shows that HisTagged SsZntA
(lane +) is stained by the InVision® dye, resulting in a clear band. Figure 9a reveals that binding of Nb1
to SsZntA allows for retention of the latter in the Ni2+-immobilized resin, proving that an Nb-SsZntA
complex forms; Nb2-4-5-8-9 behaved similarly to Nb1 (results not shown). In Figure 9b, it is verified
that the bands corresponding to SsZntA do not present a HisTag, while the Nbs do.
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Figure 8. SsZntA-Nb complex analysis using affinity chromatography: SsZntA only. (a) Chromatogram
of HisTag-free SsZntA loaded on an Ni2+-immobilized column. Without Nb, the ATPase elutes in the
flow through (control). (b) Coomassie (left) and InVision® (right) stained SDS-PAGE of HisTagged
SsZntA as positive control for the staining (+), flow through (FT), and eluted fraction (E) of HisTag free
SsZntA loaded on the Ni2+-immobilized resin as negative control.
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Figure 9. SsZntA-Nb complex analysis using affinity chromatography: SsZntA + Nb. (a) Chromatogram
of HisTag-free SsZntA incubated with HisTagged Nb1. The complex elutes at 400 mM imidazole
and is here reported as representative of the other Nbs. (b) Coomassie (top) and InVision® (bottom)
stained SDS-PAGE of the eluted fractions at 400 mM imidazole of HisTag-free SsZntA in complex with,
respectively, Nb1-2-4-5-8-9.
3.5. Nb Effect on SsZntA Functionality
We used the Baginski assay to access Nb-induced inhibition of SsZntA, which estimates the
amount of released inorganic phosphate (Pi) associated with the catalytical cycle (ATP turn-over,
1 mole Pi equals 1 mole of transported zinc). Different batches of Nbs were tested for inhibitory
activity at a molar ratio of 1 (SsZntA) to 2 (Nb), corresponding to 8 µM SsZntA and 16 µM Nbs,
yielding the results shown in Figure 10a: Wild-type SsZntA without added Nb displays a specific
activity of 885 ± 87 nmol Pi mg−1 min−1, which is comparable to the activity previously reported [18].
Nb9 reduces the ATPase activity to around 50% of wild-type, showing a significant inhibition with a
p value < 0.0001 (Dunn’s multiple comparison test). The inhibition on the ATPase activity by the other
Nbs is non-significant at the concentrations tested. We included the phosphate analog, aluminum
fluoride (AlF3), as a control of the ATPase inhibition assay at two different concentrations: 1.6 µM
(as the Nbs) and 2 mM (previously reported [3] working concentration). AlF3 does not affect ATPase
activity at 1.6 µM, showing that the affinity for SsZntA of Nb9 is higher than that of AlF3. In Figure 10b,
a titration experiment of Nb9 with different molar ratios is reported: Nb9 inhibits ATPase activity of
SsZntA when present at least at a molar ratio 1:1 (SsZntA:Nb9) and has the maximum inhibitory effect
(at about 50%) at the molar ratio of 1:3 (SsZntA:Nb9). To assess Nb9 specificity, it was further tested
against CopA from Legionella pneumophila (LpCopA): A member of the same subfamily as SsZntA
(PIB-type, 34% identity to SsZntA), but transporting Cu+ instead of Zn2+, and against CadA from
Mesorhizobium metallidurans (MmCadA); a Cd2+ and Zn2+-transporting ATPase from the same subclass
as SsZntA (PIB-2-type, 53% identity). LpCopA and MmCadA were purified similarly to SsZntA and
yield highly pure protein (Figure 11a). As shown in Figure 11b, Nb9 did not inhibit ATPase activity for
any of the two proteins, suggesting that Nb9 is specific for SsZntA.
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Figure 10. Nanobody effect on the catalytical function. (a) SsZntA was incubated with each Nb at a
1:2 molar ratio (i.e., 1.6 µM) and activity was assessed. Nb9 displayed an inhibitory effect of about
50% compared to untreated (no Nb) SsZntA. The difference between no Nb and Nb9 has a p value of
<0.0001 (*), as assessed by a Dunn’s multiple comparison test. The ATPase inhibitor aluminum fluoride
(AlF3) is shown as a positive control, at 1.6 µM (corresponding to the concentration of the tested Nbs)
and at 2 mM. (b) The inhibition stoichiometry was assessed as titration of SsZntA with different molar
ratios of Nb9. The inhibitory effect appears when Nb9 is present at a molar ratio of 1:1 (ZntA:Nb9),
and reaches the inhibitory plateau at a molar ratio of 1:3 (ZntA:Nb9), with an IC50 = 1.57 molar ratio.
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Figure 11. Nb9 specificity. (a) SDS-PAGE of purified Cu+-transporting PIB-1-ATPase from Legionella
pneumophila (LpCopA) and Cd2+ and Zn2+-transporting PIB-2-ATPase from Mesorhizobium metallidurans
(M CadA) (b) Nb9 w s tested for specificity against LpCopA and against MmCadA, in th presence
of Cu+ or Zn2+, respectively. The results are normalized for the b ckground in prese ce of the metal
ion chelato EDTA.
4. Discussion
P-type ATPases are characterized by a transmembrane domain, embedding the ion binding site(s),
and a large soluble portion, which includes catalytic and regulatory domains. Each domain has a
particular function that requires an overall maintained structural integrity: The relative arrangements
of these domains, and their ability to undergo conformational changes, is of crucial importance for
the ATPase function and the ion translocation activity [19]. Hence, ATP and phosphate analogs
(e.g., AMPPCP (Adenylylmethylenediphosphonate disodium salt) [20] or AlF3 [21]) that occupy the
nucleotide binding or phosphorylation site in the soluble portion, preventing hydrolysis, inhibit also
translocation of transported ion(s) through the transmembrane domain. In this study, Nbs were
selected as tool compounds, exploiting their ability to bind to cavities and active sites of proteins due
to a combination of the small size and convex paratope [22]. We identified Nbs that bind specifically to
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the model zinc-transporting PIB-type ATPase SsZntA to widen the toolset available for structural and
functional studies of this subclass of ATPases.
Isolated membranes containing SsZntA were solubilized in DDM, followed by detergent exchange
to C12E8 using affinity chromatography. For the samples exploited for immunization, but not
those used for selection, an additional detergent exchange to DDM was performed during SEC.
DDM is frequently the detergent of choice for membrane proteins, providing efficient solubilization,
stabilization, and preventing non-specific interaction for many membrane protein targets. This means
that DDM is suitable if the aim is to reduce interaction and aggregation with other soluble and
membrane proteins, as in the case of llama immunization. The SsZntA samples used for Nb selection
were instead purified in 0.015% w/v C12E8: This detergent provides a smaller micelle size and,
therefore, leaves more of the protein exposed for interactions. Detergents that give a small micelle size
are preferred for structural biology studies, increasing the possibility for protein-protein interactions,
which are essential for crystal-lattice formation [23]. In this work, the final aim was to provide
new tools for SsZntA crystallization, and thus the identified Nbs need to bind and/or inhibit in the
presence of the detergent used for crystallization studies of many P-type ATPases: C12E8 [3,24–26].
Therefore, the selection was performed using C12E8 solubilized SsZntA, but we anticipate similar
results in the presence of other mild detergents, including DDM.
Following screening of the initial Nb hits, we selected 11 for further studies, attempting to address
variability in the sequences. As shown in Figure 4 (b), the selected Nbs display distinct differences in
the complementarity determining regions (CDR), while the conserved motifs and predicted scaffold
structure are maintained. This observation is in line with previous findings on Nbs, since the CDRs are
constituted by residues responsible for antigen binding, and different residue combinations potentially
bind to different antigens. Among the selected 11 Nbs, one (Nb3) could not be purified and four (Nb6,
Nb7, Nb10, Nb11) caused precipitation of the sample when mixed with SsZntA, and could thus not
be tested in further assays. We believe that the observed precipitation can relate to the presence of
detergent, perhaps in combination with Nb binding, which apparently compromises SsZntA further
in this environment (e.g., through interaction with unstable intermediates or at sensitive regions of
the proteins, such as the membrane interface). We successfully identified six Nbs (Nb1, Nb2, Nb4,
Nb5, Nb8, Nb9) which bind to SsZntA, while only one (Nb9) displays significant (<50%) inhibition
of the ATPase activity. Nb9 was tested against two other members of the heavy metal-transporting
subfamily in order to assess its specificity: It does not inhibit the ATPase activity of neither a copper-
nor a zinc-transporting ATPase, denoting a high degree of specificity and a tight interaction with
specific residues and/or conformations of SsZntA, which make it an ideal tool for studying in detail
the transport cycle of this protein.
Further studies are needed to assess whether Nb9 inhibits the activity by binding between
domains (as allosteric inhibitors), or if it occupies the ATP or the metal binding site, thus inhibiting
the activity as competitive ligands, and if it blocks the reaction cycle by binding to a specific reaction
cycle state. The latter is of particular interest, since it could be the first E1-specific inhibitor to be
found for a metal-transporting P-type ATPase and would thus have extensive applications in both
structural and functional characterization efforts. The fact that five out of six Nbs bind, but do not
inhibit, the activity may hint that these Nbs associate to, for example, the more exposed portions of
the soluble domains, and not to domain-domain interfaces. In any case, they can still be exploited
as tools for structural biology studies: Co-crystallization of the Nbs with SsZntA is likely to alter
crystal contacts/crystal packing by, for instance, generating a wider hydrophilic surface for lattice
contacts. If stronger crystal contacts are obtained, it may result in an increased resolution of the
diffraction data generated from these crystals. Moreover, the identified Nbs may serve as chaperones
for cryo-EM experiments, with the aim of facilitating images’ orientation, domain identification, and to
render particles larger. In conclusion, this work provides the foundation for further usage of Nbs in
structural studies of PIB-type ATPases, aiming at expanding the available toolbox to achieve a greater
understanding of this important, yet elusive, subfamily of enzymes.
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